News
-
-
PRESS RELEASE
Amid FDA Concerns, HTL-Strefa Inc. Offers a Reliable and Safe Alternative to Chinese Supplied Needles & Syringes With European-Produced Sicura(TM) Passive Safety Needle
HTL-Strefa Inc. introduces DropSafe Sicura, the first fully passive safety needle in North America, offering a safe injection experience amidst FDA concerns over Chinese-manufactured safety needles -
PRESS RELEASE
Mace(R) Security International, a Global Leader in Personal Self-Defense Sprays, Announces Additional Unsecured Subordinated Funding
Mace Security International secures $150,000 unsecured subordinated loan from Board member to fund operational expenses and new Amazon initiative. No conversion feature. Loan matures July 27, 2025 or when senior credit repaid -
-
PRESS RELEASE
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
Jaguar Health, Inc. (NASDAQ:JAGX) will conduct an investor webcast on April 1, 2024, at 8:30 a.m. EST to review fourth-quarter financials and corporate updates. Company plans to file its Earnings Report on Form 10-K for year ended December 31, 2023 -
PRESS RELEASE
Massachusetts Governor, Senate President, Speaker of the House, Leaders of Legislature, Medicine, and Advocacy Lead the Nation in the Fight Against Prostate Cancer
AdMeTech Foundation hosts the 15th Annual Prostate Cancer Awareness Day with prominent guests and discussions on health disparities, clinical care, and research advancements -
-
PRESS RELEASE
Supporting Our Community: TAG Inc. Sponsors AdventHealth Foundation's Golf Fundraiser
TAG Inc. sponsors AdventHealth Foundation Central Florida's Sixth Annual Golf Classic, supporting vital community programs. The event brings together community partners for a day of golf and philanthropy -
-
PRESS RELEASE
FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
FSD Pharma Inc. announces agreement with iNGENu CRO Pty Ltd. to conduct a Phase 1 clinical study for novel compound Lucid-21-302 to treat MS. Company aims to develop innovative therapeutics